Q-omics provides the consensus-scored PGAM1P2 profile across patient tissues and cancer cell-line models. PGAM1P2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PGAM1P2 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, PGAM1P2 RNA expression shows 8,312 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight KICH, LUAD, and CCRCC as cancer lineages where PGAM1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGAM1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGAM1P2 survival associations across molecular data types. PGAM1P2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGAM1P2 RNA expression–survival associations across cancer types. High PGAM1P2 expression shows unfavorable associations in KICH, STAD, BLCA and LUAD, but favorable associations in SKCM and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PGAM1P2 RNA expression.
This table summarizes PGAM1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for PGAM1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGAM1P2 shows lower tumor expression in LUAD, BRCA, LUSC, KICH and KIRP and higher tumor expression in HNSC. The LUAD box plot shows higher PGAM1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.098, t-test p < 0.001).
This table shows molecular features associated with PGAM1P2 in patient tissues and cancer cell lines. In patient samples, PGAM1P2 shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
